Formylmethionine (N-Formylmethionine, fMet): A Comprehensive Reference
1. Identity and Chemical Characterization
Names and Identifiers
N-Formylmethionine (abbreviated fMet, also written HCO-Met or For-Met) is a derivative of the amino acid methionine in which a formyl group has been added to the amino group. Its full formal chemical name is N-formyl-L-methionine. Additional synonyms in the chemical literature include FMET, FOR-MET-OH, NSC 334322, For-L-Met-OH, and N-For-Met-OH. Its CAS Registry Number is 4289-98-9.
The molecular formula is C₆H₁₁NO₃S, and the formula weight is 177.2 g/mol. According to ChEBI (Chemical Entities of Biological Interest), fMet is an L-methionine derivative in which one of the hydrogens attached to the nitrogen is replaced by a formyl group. It appears as a white powder and is classified as both a microbial metabolite and a human endogenous metabolite.
Natural Sources and Occurrence
fMet plays a crucial part in the protein synthesis of bacteria, mitochondria, and chloroplasts. It is not used in cytosolic protein synthesis of eukaryotes, where eukaryotic nuclear genes are translated, and it is also not used by Archaea. This means that as an endogenous molecule, fMet is naturally present in virtually all living organisms — arising from the normal processes of bacterial translation, and from mitochondrial and chloroplastic protein synthesis in eukaryotic cells.
Traditionally attributed to bacterial and mitochondrial origins, formyl peptides derived from fMet are now proposed to arise from an additional, stress-inducible source within the eukaryotic cytosol. Recent findings suggest that under specific stress conditions, eukaryotic translation can initiate with formylmethionine (fMet), producing fMet-bearing nascent chains that are processed by the fMet/N-degron and fMet-mediated ribosome quality control (fMet-RQC) pathways.
N-terminal methionine formylation, a protein modification once thought to be exclusive to bacteria and organelles, also occurs on proteins synthesized in the cytosol of yeast and human cells, challenging long-held assumptions.
Common Forms and Preparations
As a research and analytical compound, fMet is commercially available as a synthetic white solid. It is used in laboratory research to identify, differentiate, and characterize amino acid N-deformylase(s), N-carbamoylase(s), and N-aminoacylase(s). The solid form is soluble in common laboratory solvents including DMF (16 mg/mL), DMSO (12 mg/mL), ethanol (2 mg/mL), and PBS pH 7.2 (5 mg/mL). Formyl peptides derived from fMet — such as the prototypical tripeptide N-formylmethionyl-leucyl-phenylalanine (fMLP or fMLF) — are also prepared synthetically for research applications.
Importantly, fMet is not currently recognized as a standalone dietary supplement or herbal ingredient in any major pharmacopeia, national or international regulatory framework, or official monograph. Its significance in the nutritional and health sciences context arises from its role as an endogenous biomarker and signaling molecule, not from its administration as a dietary supplement. Any claims positioning fMet primarily as a "natural health supplement" are not supported by existing regulatory classifications or clinical evidence.
2. Historical and Traditional Context
fMet does not have a history of traditional use as a botanical ingredient, herbal remedy, or dietary supplement in any documented ethnopharmacological tradition. Its existence was not known to pre-modern medicine, because it was not identified until the mid-twentieth century through biochemical research. An unexpected observation that drove its discovery was the over-representation of methionine (Met) at the N-terminal position for the vast majority of bacterial proteins. Subsequently, Marcker and Sanger (1964) discovered N-terminally formylated fMet-tRNA.
The biological relevance of fMet-initiated peptides to immunity was first appreciated experimentally in the 1970s. Studies conducted in the 1970s found that a series of N-formylmethionine-containing oligopeptides, including the most potent and best-known member of this series, N-formylmethionine-leucyl-phenylalanine (FMLP or fMet-Leu-Phe), stimulated rabbit and human neutrophils by an apparent receptor-dependent mechanism to migrate in a directional pattern in classical laboratory assays of chemotaxis.
The compound has no documented use in Ayurvedic, Traditional Chinese Medicine, Indigenous American, or European folk medicine traditions, as its existence at the molecular level was wholly unknown before mid-20th century biochemistry. All health-relevant research on fMet is therefore entirely modern and scientific in nature, dating to no earlier than the 1960s–1970s.
3. Biochemistry: Biosynthesis, Structure, and Enzymatic Processing
Biosynthesis and the Role of Transformylase
The addition of the formyl group to methionine is catalyzed by the enzyme methionyl-tRNA formyltransferase (transformylase). This modification is done after methionine has been loaded onto tRNAfMet by aminoacyl-tRNA synthetase.
The first amino acid in the synthesis of all bacterial polypeptides is N-formylmethionine (fMet) — a modified methionine residue with a formyl group attached to its amino group. Two types of methionyl-tRNA exist: one binds formylmethionine and the other binds normal methionine.
Ribosomal Initiation Mechanism
Initiation in bacteria starts with the formation of a complex between the small 30S ribosomal subunit, the mRNA, and fMet-tRNA, with the latter binding to the initiating AUG (or occasionally GUG) codon near the 5′ end of the mRNA. A 50S large ribosomal subunit then attaches to form a functional initiation complex. A number of initiation factors and GTP are also required.
N-Formylmethionine is coded by the same codon as methionine, AUG. However, AUG is also the translation initiation codon. When the codon is used for initiation, N-formylmethionine is used instead of methionine, thereby forming the first amino acid of the nascent peptide chain. When the same codon appears later in the mRNA, normal methionine is used.
Post-Translational Removal: Peptide Deformylase
When Nt-fMet-containing polypeptides emerge from a ribosomal exit tunnel, ribosome-associated peptide deformylase (PDF) removes the Nt-formyl moiety from the nascent polypeptides, generating unmodified Met at the N-termini. Thus, the population of fMet-containing proteins can be controlled by the counteractions of the formyltransferase (FMT) and PDF enzymes.
Peptide deformylase (PDF) is a metal-containing hydrolase responsible for removing the N-terminal formyl group from the nascent protein. It is an essential enzyme for bacteria but not required in mammalian cells, which makes it a promising target for the development of new antibiotics.
The fMet/N-Degron Pathway
In addition to its role in the initiation of protein synthesis, Nt-fMet can function as a specific protein degradation signal in cellular proteins, termed the fMet/N-degron, targeted by the eukaryotic fMet/N-degron pathway.
fMet contributes to protein synthesis, stability, and cellular stress responses, particularly through the fMet-ribosome quality control and fMet/N-degron pathways. By coupling the stress-induced synthesis of cytosolic fMet-containing proteins to their selective removal, these pathways help maintain proteostasis and promote cellular adaptation.
In addition to these fundamental roles in protein synthesis and degradation, bacterial and mitochondrial Nt-formylated proteins are sources of N-formyl peptides that elicit immune responses via formyl peptide receptor–mediated signaling pathways. Nt-formylation on mitochondrial DNA–encoded proteins substantially contributes to the steady-state level and organization of oxidative phosphorylation complexes.
4. Key Mechanisms of Action
4.1 Innate Immune Signaling via Formyl Peptide Receptors (FPRs)
The prototypical fMet-containing oligopeptide is N-formylmethionine-leucyl-phenylalanine (FMLP), which activates leukocytes and other cell types by binding with these cells' formyl peptide receptor 1 (FPR1) and formyl peptide receptor 2 (FPR2) G protein-coupled receptors.
FPR1 selectively triggers distinct signaling pathways in human peripheral blood neutrophils based on different concentrations of fMLF; subnanomolar concentrations of fMLF induced chemotaxis and conformational change of FPR1, whereas nanomolar and micromolar concentrations were responsible for degranulation and superoxide generation.
Activation of neutrophils by fMet via FPR1 triggers a wide variety of downstream effector functions, including chemotaxis, degranulation, ROS production, and phagocytosis, bridging an association between mitochondrial fMet proteins, FPR1, and neutrophil activation.
4.2 The "Danger Signal" Model
In the human body, fMet is recognized by the immune system as foreign material, or as an alarm signal released by damaged cells, and stimulates the body to fight against potential infection.
Since fMet is present in proteins made by mitochondria and chloroplasts, more recent theories do not see it as a molecule that the immune system can use to distinguish self from non-self. Instead, fMet-containing oligopeptides and proteins appear to be released by the mitochondria of damaged tissues as well as by damaged bacteria, and can thus qualify as an "alarm" signal, as discussed in the Danger model of immunity.
fMLF can act as a "find-me" signal, released by dead or dying cells to attract phagocytes to those cells, so that the phagocytes phagocytose the dead or dying cells, thereby clearing up the damage.
4.3 Mitochondrial Proteostasis and the N-Degron Pathway
During prolonged stress, newly synthesized fMet proteins undergo maturation or selective degradation via the fMet/N-degron pathway. Proteolytic clearance of cytosolic fMet substrates releases formylated peptides and free fMet, which are elevated in critical illness and activate formyl peptide receptors — linking translation surveillance to innate immune and inflammatory signaling in sepsis and age-related disease.
In human cytoplasmic hybrid (cybrid) lines, fMet modulated both mitochondrial and cytosolic proteins on multiple levels, through transcription, post-translational modification, and proteolysis by an N-degron pathway, abolishing known differences between mtDNA haplogroups.
4.4 Vascular and Cardiovascular Mechanisms
Mechanistically, fMet likely contributes to elevated blood pressure by suppressing endothelial nitric oxide synthase expression and inducing oxidative stress and mitochondrial dysfunction in endothelial cells. In addition, fMet elicited an early inflammatory response, disrupted the endothelial barrier, and upregulated myosin light chain expression in vascular smooth muscle.
5. Scientific Evidence by Area of Use or Association
5.1 Cardiovascular Disease and Hypertension
Evidence level: Human observational/epidemiological — strong associations established; causal mechanisms under investigation.
A landmark study published in Nature Medicine (2021) examined 5,689 blood-derived biomarkers in relation to mitochondrial DNA variants. Undertaking a hypothesis-free analysis of 5,689 blood-derived biomarkers with mtDNA variants in 16,220 healthy donors, the authors showed that variants defining mtDNA haplogroups Uk and H4 modulate the level of circulating N-formylmethionine (fMet), which initiates mitochondrial protein translation. In a further 11,966 individuals, fMet levels contributed to all-cause mortality and the disease risk of several common cardiovascular disorders. Together, these findings indicate that fMet plays a key role in common age-related disease through pleiotropic effects on cell proteostasis.
Statistical analysis defined a positive correlation between fMet concentration and the risk of various age-associated illnesses, including heart failure and coronary artery disease. This indicates that fMet is a potential biomarker for various age-related diseases.
A more recent study in Hypertension investigated fMet and blood pressure across a multiethnic population. The plasma metabolite N-formylmethionine (fMet) showed the most consistent associations with blood pressure across age, sex, and ethnicity. Notably, fMet was associated with higher systolic (+4.14 mm Hg, 95% CI, 2.11–6.17 per SD increase) and diastolic BP (+2.61 mm Hg, 1.41–3.82), and these associations were validated in 2 independent cohorts. The study identified fMet as a novel independent factor associated with blood pressure in an ethnically diverse population, likely contributing to higher BP by triggering endothelial cell dysfunction while augmenting contractile proteins in vascular smooth muscle cells.
Levels of N-formylmethionine are positively correlated with the incidence of renal disease, heart failure, coronary artery disease, abdominal aortic aneurysms, and chronic obstructive pulmonary disease (COPD), as well as mortality.
Limitations: These studies are observational or epidemiological in design. They demonstrate associations between circulating fMet levels and disease risk, but do not establish that modifying fMet levels through supplementation or intervention would reduce cardiovascular risk. No interventional clinical trials supplementing fMet have been conducted.
5.2 Critical Illness, Sepsis, and ARDS
Evidence level: Human observational, multicohort metabolomics — preliminary but consistent.
A multicohort metabolomics study published in Critical Care examined circulating fMet levels in ICU patients. Cell stress promotes degradation of mitochondria, which release danger-associated molecular patterns that are catabolized to N-formylmethionine. The authors hypothesized that in critically ill adults, the response to N-formylmethionine is associated with increases in metabolomic shift-related metabolites and increases in 28-day mortality. Patients with the top quartile of N-formylmethionine abundance at ICU admission had a significantly higher adjusted odds of 28-day mortality in the VITdAL-ICU cohort (OR, 2.4; 95%CI 1.5–4.0; P = 0.001) and the RoCI cohort (OR, 5.1; 95%CI 1.4–18.7; P = 0.015). The results indicate that circulating N-formylmethionine promotes a metabolic shift with heightened mortality that involves incomplete mitochondrial fatty acid oxidation, increased branched chain amino acid metabolism, and activation of the pentose phosphate pathway.
Limitations: This study is observational and cannot determine whether elevated fMet is a cause of worse outcomes or merely a marker of more severe mitochondrial stress. No interventional trials based on these findings have been reported.
5.3 Rheumatoid Arthritis and Autoimmune Inflammatory Disease
Evidence level: Human observational cohort studies — moderate, consistent across multiple cohorts.
Literature suggests that neutrophils of patients with rheumatoid arthritis (RA) are primed to respond to N-formyl methionine group (formylated peptides). Animal models indicate that formylated peptides contribute to joint damage via neutrophil recruitment and inflammation in joints.
A study published in the Journal of Autoimmunity (2021) analyzed fMet levels across multiple RA cohorts. Levels of mtNFPs (total fMet, MT-ND6) were analyzed using ELISA in plasma and serum obtained from patients in 3 cross-sectional RA cohorts (n = 275), a longitudinal inception cohort (n = 192) followed for a median of 8 years. Baseline levels of total fMet correlated with current and future joint involvement and predicted the development of rheumatoid nodules (OR = 1.2, p = 0.04). Further, total fMet levels improved the prognostic ability of anti-citrullinated protein antibody (ACPA) in predicting erosive disease (OR of 7.9, p = 0.001). Total fMet levels correlated with markers of inflammation and neutrophil activation. Circulating mtNFPs induced neutrophil activation in vitro through FPR1-dependent mechanisms.
In systemic sclerosis (SSc), a related autoimmune connective tissue disorder: Elevated levels of fMet peptides were found in SSc patients, prompting investigation of their role in neutrophil activation. Additionally, increased levels of fMet were observed in diffuse cutaneous SSc (DcSSc) as compared to limited cutaneous SSc (LcSSc) patients, suggesting fMet levels might play an important role in the pathogenesis of DcSSc and could serve as a useful serological marker for evaluating the type of SSc disease.
A 2025 study in the Journal of Internal Medicine investigated fMet in RA-associated interstitial lung disease. Plasma and sputum levels of fMet and neutrophil activation markers were measured by ELISA in two cohorts (n = 269 and 314) spanning multiple disease subgroups. Calprotectin levels were significantly elevated in RA-ILD patients compared to controls and RA-noILD patients (p < 0.05), and were negatively correlated with pulmonary function in RA. Plasma fMet levels were higher in RA-ILD patients compared to healthy controls (p < 0.0001) as well as compared to RA-noILD patients (p < 0.01), with a significant inverse correlation to pulmonary function in RA patients. The fMET–FPR1 axis was associated with neutrophil activation in RA-ILD and defines inflammatory endotypes associated with lung impairment.
Limitations: All human studies in this area are observational. The therapeutic question — whether blocking or modulating fMet/FPR1 signaling can ameliorate disease — has not been tested in human clinical trials.
5.4 COVID-19 and Infectious Disease
Evidence level: Human observational — preliminary.
A study published in Virulence investigated mitochondrial N-formyl methionine peptides in COVID-19 patients, finding that these peptides contribute to exaggerated neutrophil activation. Elevated levels of both calprotectin and neutrophil extracellular traps (NETs) have been found in several infectious and inflammation-associated diseases, such as sepsis, ARDS, rheumatoid arthritis, systemic sclerosis, and systemic lupus erythematosus. Similarly, neutrophil activation markers calprotectin and NETs have been reported to be significantly increased in COVID-19.
Limitations: Research in this area remains at the observational and mechanistic stage. No clinical interventions targeting the fMet/FPR axis in COVID-19 have been reported.
5.5 Cancer Biology
Evidence level: Preclinical only (cell culture and animal models).
A 2024 study in Scientific Reports examined the role of cytosolic fMet in colorectal cancer. Removal of the Nt-formyl moiety of Nt-fMet-containing proteins (via expressing E. coli PDF peptide deformylase) resulted in a dramatic increase in the proliferation of SW480 colorectal cancer cells. This proliferation coincided with the acquisition of cancer stem cell features, including reduced cell size, enhanced self-renewal capacity, and elevated levels of cancer stem cell surface marker CD24 and pluripotent transcription factor SOX2. Furthermore, deformylation of Nt-fMet-containing proteins promoted the tumorigenicity of SW480 colorectal cancer cells in an in vivo xenograft mouse model. These findings suggest that cytosolic deformylation has a tumor-enhancing effect, highlighting its therapeutic potential for cancer treatment.
In human colorectal cancer cells, cytosolic Nt-Met formylation exhibits anti-tumorigenic properties, whereas cytosolic Nt-fMet deformylation is associated with enhanced cancer proliferation and cancer stem cell-like characteristics.
Limitations: All cancer-related findings are preclinical (cell lines and mouse xenograft models). No human clinical studies exist in this area.
5.6 Antimicrobial Drug Development (Pharmacological Target)
Evidence level: Preclinical/biochemical — active research field, no approved drugs to date directly based on fMet modification.
The unique role of fMet in prokaryotic — but not mammalian cytosolic — protein synthesis has made bacterial peptide deformylase (PDF) an intensely studied antibiotic target. Peptide deformylase catalyzes the deformylation reaction of the amino terminal fMet residue of newly synthesized proteins in bacteria, and most likely in Plasmodium falciparum, and has therefore been identified as a potential antibacterial and antimalarial drug target.
An ideal antibacterial target should be present in most human pathogens, absent from human cells, part of an essential pathway in the pathogen, not inhibited by widely used antibiotics, and highly specific for the pathogen and non-toxic for humans. Peptide deformylase (PDF) has been suggested as a possible candidate that may fulfil all these criteria.
The inhibition of E. coli growth could be counteracted by overexpression of PDF from different organisms, including E. coli, Streptococcus pneumoniae, and Haemophilus influenzae. Conversely, reduced expression of PDF in S. pneumoniae resulted in an increased susceptibility to the inhibitors. Proteome analysis on two-dimensional gels revealed a shift for many proteins towards lower pI in the presence of PDF inhibitors, as would be expected if the proteins still carry their N-formyl-Met terminus.
5.7 Bone and Musculoskeletal Biology
Evidence level: Preclinical and limited human observational data.
FPRs can play a major role in osteoblast differentiation from mesenchymal stem cells (MSCs). FPR1 expression significantly increased as MSCs differentiated into osteoblasts, while fMLP was able to suppress differentiation of bone marrow-derived monocytes into osteoclasts. These findings are entirely preclinical.
6. Body Systems and Health Areas of Association
- Immune System: The endogenous E. coli peptide fMLP was isolated and its potent chemotactic effects on neutrophils were demonstrated. These results, along with work with N-formylmethionine from Staphylococcus aureus cultures and studies on synthetically synthesized N-formylmethionine peptides, support the theory that N-formylmethionine peptides originating from bacterial sources are strong mediators of neutrophil chemotaxis to sites of infection, driving an innate immune response through FPRs.
- Cardiovascular System: Multiple age-associated diseases, including cardiovascular disorders, have a positive correlation to blood fMet levels through an as-yet-unknown pathway or pathways.
- Mitochondrial Biology / Energy Metabolism: Circulating N-formylmethionine promotes a metabolic shift that involves incomplete mitochondrial fatty acid oxidation, increased branched chain amino acid metabolism, and activation of the pentose phosphate pathway.
- Inflammatory and Autoimmune Conditions: fMet and fMet-derived peptides are implicated in the pathogenesis of rheumatoid arthritis, systemic sclerosis, and RA-associated interstitial lung disease through the fMET–FPR1 axis.
- Cellular Proteostasis: Nt-formylation greatly expands the functional and mechanistic complexities of the cellular proteome and plays pivotal roles in a vast range of physiological and pathological processes.
- Cancer Biology: Cytosolic fMet modifications influence colorectal cancer cell behavior and tumor-promoting properties in preclinical models.
- Pulmonary System: fMet has been identified as elevated in ARDS, COVID-19, and RA-associated interstitial lung disease cohorts.
7. Dosage Forms and Dosages Reported in Research
fMet is not available as a consumer dietary supplement with established dosage guidelines. In research settings, it is used as a biochemical standard or research chemical. No human interventional clinical trials have been conducted in which fMet was administered as an oral or injectable supplement to assess dosing, efficacy, or safety.
In immunological and cell biology research, the synthetic fMet-containing tripeptide fMLP (N-formylmethionyl-leucyl-phenylalanine) has been used in in vitro assays and occasional experimental human or animal protocols to stimulate neutrophil activity. Subnanomolar concentrations of fMLF induced chemotaxis and conformational change of FPR1, whereas nanomolar and micromolar concentrations were responsible for degranulation and superoxide generation in human peripheral blood neutrophils. These are research concentrations and have no established relevance to supplemental dosing in humans.
In the clinical biomarker studies cited above — such as the Nature Medicine study (Cai et al., 2021) and the multicohort critical illness study — fMet was measured as a circulating plasma/serum metabolite using mass spectrometry and ELISA, not administered as a therapeutic agent. No safe or efficacious supplemental dosage has been defined in any published source.
8. Safety Considerations and Known Interactions
8.1 Endogenous Molecule Status
fMet is an endogenous molecule present in all humans as a consequence of normal mitochondrial and bacterial (commensal microbiome) metabolism. Proteolytic clearance of cytosolic fMet substrates releases formylated peptides and free fMet, which are elevated in critical illness and activate formyl peptide receptors — linking translation surveillance to innate immune and inflammatory signaling in sepsis and age-related disease. This indicates that elevated circulating fMet is associated with adverse outcomes, not beneficial ones, in the context of critical illness.
8.2 Pro-inflammatory Potential
Non-steroidal anti-inflammatory drugs (NSAIDs) are known to inhibit formyl peptide-induced neutrophil activation. This pharmacological observation underscores that fMet-mediated FPR signaling is a pro-inflammatory pathway, and its exogenous amplification could theoretically exacerbate inflammatory conditions. No human safety studies have investigated the effects of administered exogenous fMet.
8.3 Association with Disease States at Elevated Levels
Levels of N-formylmethionine are positively correlated with the incidence of renal disease, heart failure, coronary artery disease, abdominal aortic aneurysms, chronic obstructive pulmonary disease (COPD), as well as mortality. This epidemiological association suggests that higher circulating fMet is linked to adverse health outcomes, though the directionality of causation is not established.
Mechanistically, fMet likely contributes to elevated blood pressure by suppressing endothelial nitric oxide synthase expression and inducing oxidative stress and mitochondrial dysfunction in endothelial cells.
8.4 Regulatory and Research Chemical Status
In commercially available forms, fMet is explicitly a research chemical. Major suppliers explicitly state that their products are "for research use only, not for human use." No approved drug, approved dietary supplement, or monographed herbal ingredient based on formylmethionine exists in the United States, European Union, or other major regulatory jurisdictions as of the time of this writing. The European Pharmacopoeia, United States Pharmacopeia, WHO monographs, German Commission E, and ESCOP do not contain monographs for formylmethionine.
8.5 Leucocyte fMet Deformylase in Human Cells
Extracts of human neutrophils, lymphocytes, and platelets enzymatically deformylate N-formyl-L-methionine. Enzyme activity is stimulated by Co²⁺, inhibited by bivalent-cation chelators, and unaffected by inhibitors of serine, thiol, and carboxyl proteinases. This demonstrates that human immune cells possess machinery to metabolize fMet, which has implications for how orally administered fMet (if it were to be studied) might be handled in the body.
9. Current Research Directions and Evidence Gaps
The team identified associations between mtDNA variants and N-formylmethionine (fMet) and effects of fMet on the risk of developing a range of common, late-onset illnesses, and noted that further study of the molecular mechanisms at work is required. N-formylmethionine (fMet) is a promising biomarker that could one day help monitor individual disease risk and plan pre-emptive interventions.
The findings highlight the evolutionary conservation of N-terminal methionine formylation and its potential implications in stress adaptation, cancer, and immune signaling. Future studies should identify Nt-formylated proteins across different conditions and explore the therapeutic potential of targeting this modification.
Advances in N-terminomics and anti-fMet reagents now allow direct detection and quantification of cytosolic fMet proteoforms. This area of research integrates bacterial and organellar paradigms with emerging cytosolic mechanisms, examines regulatory gating of Nt-formylation, and highlights therapeutic strategies to restore proteostasis and counter fMet-associated pathology.
A critical unresolved question concerns the origins of fMet in eukaryotic cells under stress. A recent study revealed the possibility of fMet as a signaling molecule that affects mitochondria and the cytoplasm, thus providing a possible explanation for the conservation of fMet across multiple species. Although the significance of this study should not be overlooked, many questions remain unanswered.
Summary of Evidence Strength by Application Area
- Prokaryotic protein synthesis initiation: Established molecular biology; not clinically applied.
- Innate immune signaling (neutrophil chemotaxis via FPR1/FPR2): Well-established in human cells and corroborated by multiple studies; no clinical therapeutic application approved.
- Biomarker for cardiovascular disease and mortality: Strong epidemiological associations across large human cohorts (up to ~28,000 individuals total); causal mechanisms under active investigation; no interventional trials.
- Rheumatoid arthritis activity and prognosis: Consistent across multiple human cohorts; observational only.
- Critical illness / ICU mortality prediction: Multicohort observational; promising but not yet clinical practice.
- Antibiotic drug target (peptide deformylase inhibition): Active preclinical/drug development research; no approved drugs as of this writing.
- Cancer biology: Preclinical only.
- Dietary supplement / exogenous health benefit: No human clinical evidence of benefit from supplementation; not studied in this context.
References
Go back